This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Scary Monetary Policy Calls: Global Week Ahead
by Mark Vickery
In the Global Week Ahead, big market-moving events are likely to hail from the monetary policy arena.
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.
Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA
by Zacks Equity Research
The FDA extends the review period for Roche's sBLA for Tecentriq in combination with Avastin for the initial treatment of NSCLC by three months.
The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants
Novartis to Sell Sandoz's Dermatology Business to Aurobindo
by Zacks Equity Research
Novartis (NVS) looks to sell Sandoz's dermatology business in the United States and generic U.S. oral solids portfolio, to Aurobindo Pharma USA Inc., for $0.9 billion.
September Bogging You? Look at the Best 9-Month Run Instead
by Tirthankar Chakraborty
During midterm election years, Q4 delivers a 6.7% jump on average for the S&P 500, while the index registers gains of 5.2% and 4.5% for the next year's Q1 and Q2, respectively.
Large Cap Pharma Stocks Staging a Comeback in Second Half
by Indrajit Bandyopadhyay
Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.
J&J Submits NDA to the FDA for Depression Drug in Adults
by Zacks Equity Research
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Cleveland-Cliffs, Callaway Golf, SkyWest and Vishay Intertechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Cleveland-Cliffs, Callaway Golf, SkyWest and Vishay Intertechnology
AstraZeneca Up This Year So Far on Favorable Pipeline Updates
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Qualcomm, Citigroup, Diageo and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Qualcomm, Citigroup, Diageo and Anthem
5 Top Stocks to Challenge a Notorious September
by Tirthankar Chakraborty
Among the two pillars of the U.S. economy, consumer confidence is strong and corporate earnings continue to grow.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Merck (MRK) Receives FDA Approval for Two HIV Medicines
by Zacks Equity Research
Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.
Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for label expansion of Sprycel for the treatment of pediatric patients with newly diagnosed Ph+ ALL.
Glaxo's Asthma Drug Gets EU Nod for Pediatric Population
by Zacks Equity Research
Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Top Stock Reports for Bristol-Myers, Qualcomm & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), Qualcomm (QCOM) and Citigroup (C).
Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease
by Zacks Equity Research
Novartis' (NVS) BRAF/MEK inhibitor combination, Tafinlar plus Mekinist, gets approval in the EU for adjuvant treatment of BRAF V600 mutation-positive melanoma.
Pfizer Stock Up This Year So Far: What's Going in its Favor?
by Zacks Equity Research
Pfizer's (PFE) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
The Zacks Analyst Blog Highlights: Amazon, Microsoft, Apple, Bristol-Myers and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Microsoft, Apple, Bristol-Myers and Celgene
R&D Spending Hits the Fastest Pace in 12 Years: Top 5 Winners
by Tirthankar Chakraborty
Given the importance of R&D and the pace at which it has picked up, investing in stocks that are spending big on tomorrow's ideas is the best thing to do right now.
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
by Zacks Equity Research
The FDA granted priority review to the Bristol-Myers' (BMY) label expansion application for Empliciti seeking approval of the drug in combination with Pomalyst in multiple myeloma patients who are resistant to Revlimid.
Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
by Zacks Equity Research
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
Pfizer Amends Xtandi Study Protocols to Speed Up Completion
by Zacks Equity Research
Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer, advancing anticipated completion date.